Literature DB >> 21626415

Immunosuppressive tumor microenvironment in cervical cancer patients.

Sytse J Piersma1.   

Abstract

Cervical cancer is caused by Human papillomavirus (HPV) in virtually all cases. These HPV-induced cancers express the viral oncogenes E6 and E7 and are therefore potentially recognized by the immune system. Despite the abundant presence of these foreign antigens, the immune system is unable to cope with the tumor. Due to the constant immunological pressure, cervical cancers can evolve different immune evasion strategies, which will be described in the current review. Several approaches for immunotherapy of cervical cancer are currently under development, which aim at inducing strong HPV-specific immunity. Besides the reinforcement of potent anti-tumor immune responses, immunotherapy could also enhance HPV-specific T regulatory cells. Supplementary strategies that neutralize an immunosuppressive milieu may have great potential. These strategies are discussed as well.

Entities:  

Year:  2011        PMID: 21626415      PMCID: PMC3234326          DOI: 10.1007/s12307-011-0066-7

Source DB:  PubMed          Journal:  Cancer Microenviron        ISSN: 1875-2284


  184 in total

1.  A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation).

Authors:  Subhra K Biswas; Lisa Gangi; Saki Paul; Tiziana Schioppa; Alessandra Saccani; Marina Sironi; Barbara Bottazzi; Andrea Doni; Bronte Vincenzo; Fabio Pasqualini; Luca Vago; Manuela Nebuloni; Alberto Mantovani; Antonio Sica
Journal:  Blood       Date:  2005-11-03       Impact factor: 22.113

Review 2.  How do cytotoxic lymphocytes kill their targets?

Authors:  S Shresta; C T Pham; D A Thomas; T A Graubert; T J Ley
Journal:  Curr Opin Immunol       Date:  1998-10       Impact factor: 7.486

Review 3.  Cancer immunoediting: from immunosurveillance to tumor escape.

Authors:  Gavin P Dunn; Allen T Bruce; Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

4.  Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors.

Authors:  J P Medema; J de Jong; L T Peltenburg; E M Verdegaal; A Gorter; S A Bres; K L Franken; M Hahne; J P Albar; C J Melief; R Offringa
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-18       Impact factor: 11.205

5.  Cyclophosphamide enhances anti-tumor effect of wild-type p53-specific CTL.

Authors:  M P Vierboom; G M Bos; M Ooms; R Offringa; C J Melief
Journal:  Int J Cancer       Date:  2000-07-15       Impact factor: 7.396

6.  Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine.

Authors:  Paola Filipazzi; Roberta Valenti; Veronica Huber; Lorenzo Pilla; Paola Canese; Manuela Iero; Chiara Castelli; Luigi Mariani; Giorgio Parmiani; Licia Rivoltini
Journal:  J Clin Oncol       Date:  2007-06-20       Impact factor: 44.544

Review 7.  The B7 family and cancer therapy: costimulation and coinhibition.

Authors:  Xingxing Zang; James P Allison
Journal:  Clin Cancer Res       Date:  2007-09-15       Impact factor: 12.531

8.  Human papilloma virus specific T cells infiltrating cervical cancer and draining lymph nodes show remarkably frequent use of HLA-DQ and -DP as a restriction element.

Authors:  Sytse J Piersma; Marij J P Welters; Jeanette M van der Hulst; Judith N Kloth; Kitty M C Kwappenberg; Baptist J Trimbos; Cornelis J M Melief; Bart W Hellebrekers; Gert Jan Fleuren; Gemma G Kenter; Rienk Offringa; Sjoerd H van der Burg
Journal:  Int J Cancer       Date:  2008-02-01       Impact factor: 7.396

Review 9.  Negative regulators of T-cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections.

Authors:  Tsvetelina Pentcheva-Hoang; Emily Corse; James P Allison
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

10.  Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression.

Authors:  C Uyttenhove; J Maryanski; T Boon
Journal:  J Exp Med       Date:  1983-03-01       Impact factor: 14.307

View more
  43 in total

Review 1.  Hydrogels and scaffolds for immunomodulation.

Authors:  Ankur Singh; Nicholas A Peppas
Journal:  Adv Mater       Date:  2014-08-25       Impact factor: 30.849

2.  A synthetic chimeric peptide harboring human papillomavirus 16 cytotoxic T lymphocyte epitopes shows therapeutic potential in a murine model of cervical cancer.

Authors:  Chandresh Sharma; M A Khan; Teena Mohan; Jatin Shrinet; N Latha; Neeta Singh
Journal:  Immunol Res       Date:  2014-01       Impact factor: 2.829

3.  Circulating and tumor-infiltrating myeloid-derived suppressor cells in cervical carcinoma patients.

Authors:  Liangliang Wu; Hongyu Liu; Hongchuan Guo; Qiong Wu; Songyan Yu; Yuanyuan Qin; Gang Wang; Qiyan Wu; Rong Zhang; Lingxiong Wang; Lijun Zhang; Chunxi Liu; Shunchang Jiao; Tianyi Liu
Journal:  Oncol Lett       Date:  2018-04-18       Impact factor: 2.967

4.  A novel dendritic cell targeting HPV16 E7 synthetic vaccine in combination with PD-L1 blockade elicits therapeutic antitumor immunity in mice.

Authors:  Zhida Liu; Hang Zhou; Wenjun Wang; Yang-Xin Fu; Mingzhao Zhu
Journal:  Oncoimmunology       Date:  2016-03-10       Impact factor: 8.110

Review 5.  Advances in immunotherapy delivery from implantable and injectable biomaterials.

Authors:  David G Leach; Simon Young; Jeffrey D Hartgerink
Journal:  Acta Biomater       Date:  2019-02-13       Impact factor: 8.947

6.  Effect of human papillomavirus infection on the immune system and its role in the course of cervical cancer.

Authors:  Dan Song; Hong Li; Haibo Li; Jianrong Dai
Journal:  Oncol Lett       Date:  2015-05-29       Impact factor: 2.967

Review 7.  The immunological contribution of NF-κB within the tumor microenvironment: a potential protective role of zinc as an anti-tumor agent.

Authors:  Bin Bao; Archana Thakur; Yiwei Li; Aamir Ahmad; Asfar S Azmi; Sanjeev Banerjee; Dejuan Kong; Shadan Ali; Lawrence G Lum; Fazlul H Sarkar
Journal:  Biochim Biophys Acta       Date:  2011-11-29

8.  Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model.

Authors:  Benjamin Y Jin; Tracy E Campbell; Lindsey M Draper; Sanja Stevanović; Bianca Weissbrich; Zhiya Yu; Nicholas P Restifo; Steven A Rosenberg; Cornelia L Trimble; Christian S Hinrichs
Journal:  JCI Insight       Date:  2018-04-19

9.  Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer.

Authors:  Emeka K Enwere; Elizabeth N Kornaga; Michelle Dean; Theodora A Koulis; Tien Phan; Maria Kalantarian; Martin Köbel; Prafull Ghatage; Anthony M Magliocco; Susan P Lees-Miller; Corinne M Doll
Journal:  Mod Pathol       Date:  2017-01-06       Impact factor: 7.842

Review 10.  Targeted Agents in Cervical Cancer: Beyond Bevacizumab.

Authors:  Gloria Marquina; Aranzazu Manzano; Antonio Casado
Journal:  Curr Oncol Rep       Date:  2018-04-02       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.